Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3% on Wednesday following the announcement that the company obtained 510(k) ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now ...

Heart failure, a condition where the heart struggles to pump blood efficiently to meet the body's needs, comes in various forms and one of them, heart failure with preserved ejection fraction ...

Part 3: Heart Failure With Reduced Ejection Fraction: Diagnosis and Evaluation. Part 4: Case Study: Lightheadedness, Fatigue in Man With Hypertension. Up next: Medical Management ...

While heart failure overall is decreasing in age-specific incidence, the trends diverge by ejection fraction. For example, in a study from the Minnesota county near the Mayo Clinic, age- and sex ...